Hygea Medical

Hygea Medical (海杰亚医疗) is a Beijing-based medical device company founded in 2010, focused on minimally invasive tumor interventional therapy and cryomedicine . It has built a research and development platform around a Beijing municipal key laboratory in low-temperature biomedical engineering and a post-doctoral workstation, and is recognized as a national high-tech enterprise and a national "little giant" specialized firm .

The company's flagship product is the Kangbo Knife (康博刀), a world-first composite cryoablation system that combines deep-low-temperature freezing with high-intensity thermal therapy for solid tumors including lung, liver, breast, kidney, pancreatic, and bone cancers . The device received approval through China's innovative medical device fast-track pathway and was included in the national medical insurance catalog in 2021 . Hygea positions itself as an integrated platform offering a full range of interventional oncology diagnosis and treatment solutions .

In funding history, Gaorong Ventures exclusively led its Series C+ round in 2021, then re-upped in a Series D round led by IN Capital in early 2023 that reached several hundred million RMB in first closing . Elsewhere's corpus does not cover developments beyond early 2023.